Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study
| Autor: | Cocco, E, Sardu, C, Gallo, P, Capra, R, Amato, Mp, Trojano, M, Uccelli, A, Marrosu, Mg, Galeotti, M, Cordioli, C, Massole, S, Musu, L, Coghe, G, Patti, Francesco, Lugaresi, A, Tola, Mr, Zipoli, V, Mancardi, Gl, Capello, E, Solaro, C, Caputo, C, Cavarretta, R, Merelli, E, Perini, P, Francia, A, Batocchi, Ap, Ergamaschi, R, Tavazzi, E, Cavalla, P, Masera, S, Bertolotto, A, Capobianco, M, Zorzon, M, Ghezzi, A, Zaffaroni, M. |
|---|---|
| Přispěvatelé: | COCCO E, SARDU C, GALLO P, CAPRA R, AMATO MP, TROJANO M, UCCELLI A, MARROSU MG, THE FEMIMS GROUP, A. LUGARESI |
| Jazyk: | angličtina |
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male Questionnaires medicine.medical_specialty Multiple Sclerosis media_common.quotation_subject Fertility Young Adult Risk Factors Internal medicine medicine Humans Risk factor Young adult Amenorrhea media_common Retrospective Studies Menarche Mitoxantrone Cumulative dose business.industry Retrospective cohort study medicine.disease multiple sclerosis mitoxantrone treatment amenorrhea drug therapy/epidemiology Menopause Settore MED/26 - NEUROLOGIA Endocrinology Neurology Adult Amenorrhea chemically induced/epidemiology Female Follow-Up Studies Humans Immunosuppressive Agents adverse effects Infertility Female chemically induced/epidemiology Male Menarche Menopause Mitoxantrone adverse effects Multiple Sclerosis drug therapy/epidemiology Questionnaires Retrospective Studies Risk Factors Young Adult Infertility adverse effects chemically induced/epidemiology Neurology (clinical) medicine.symptom business Infertility Female Immunosuppressive Agents medicine.drug Follow-Up Studies |
| Popis: | Background Improved prognosis in women with multiple sclerosis (MS) undergoing immunosuppressive treatment with mitoxantrone (MITO) has led to an increased interest in the effect of such treatments on fertility. FErtility and Mitoxantrone In MS (FEMIMS) is a collaborative retrospective study aimed at evaluating the impact of MITO treatment on fertility in women with MS. Methods Occurrence of chemotherapy-induced amenorrhea (CIA) was evaluated in 189 women with MS treated with MITO before the age of 45. An “ad hoc” questionnaire, paying particular attention to onset of CIA either during or post-MITO treatment, was administered to each patient. The probability of CIA was calculated using a multivariate logistic regression analysis taking into account age at exposure, cumulative dose, and use of estroprogestinic (EP) drugs during treatment. Results Forty-eight (26%) patients presented CIA following MITO. The probability of CIA was increased by 2%/mg/m2 of cumulative dose and by 18% for each year of age, whereas it was reduced by administration of EP during treatment. Conclusions MITO treatment may affect reproductive capacity in women with MS. Patients of childbearing age should be properly counseled before MITO treatment and EP therapy should be administered to reduce the risk of CIA. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|